![Matthew A. Cooper](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Matthew A. Cooper
Gründer bei Inflazome Ltd.
Aktive Positionen von Matthew A. Cooper
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Inflazome Ltd.
![]() Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Direktor/Vorstandsmitglied | 01.01.2016 | - |
Vorstandsvorsitzender | 01.01.2016 | - | |
Gründer | 01.01.2016 | - | |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 20.07.2022 | - |
Karriereverlauf von Matthew A. Cooper
Ehemalige bekannte Positionen von Matthew A. Cooper
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Akubio Ltd.
![]() Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2001 | 31.05.2010 |
Gründer | 01.08.2001 | 31.05.2010 | |
University of Cambridge | Corporate Officer/Principal | - | - |
Ausbildung von Matthew A. Cooper
University of Adelaide | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 3 |
Australien | 2 |
Irland | 2 |
Operativ
Founder | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sektoral
Consumer Services | 3 |
Electronic Technology | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Akubio Ltd.
![]() Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Electronic Technology |
Inflazome Ltd.
![]() Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Health Technology |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
- Börse
- Insiders
- Matthew A. Cooper
- Erfahrung